EG384244 Activators
Foxl3, a member of the forkhead box family, stands as a pivotal DNA-binding transcription factor with a predicted role in RNA polymerase II-specific and cis-regulatory region sequence-specific DNA binding activities. This multifaceted gene is implicated in diverse cellular processes, including anatomical structure morphogenesis, cell differentiation, and the regulation of transcription by RNA polymerase II. Its importance is underscored by its potential influence on the intricate orchestration of genetic expression, steering cellular development and transcriptional regulation. The activation of Foxl3 is a complex process governed by a spectrum of regulatory mechanisms that delicately modulate its transcriptional activity. The intricacies involve the interplay of various cellular signaling pathways and the epigenetic landscape. For instance, histone modifications, such as acetylation, play a crucial role in Foxl3 activation, with certain chemicals influencing the enzymes responsible for these modifications. Additionally, the modulation of signaling pathways, including TGF-β, PI3K, and JNK, contributes to the nuanced activation of Foxl3. This diverse set of regulatory elements highlights the adaptability of Foxl3 in responding to different cellular cues, allowing it to fulfill its roles in transcriptional regulation and cell differentiation.
The general mechanisms of Foxl3 activation showcase its responsiveness to a range of chemical cues, emphasizing its role as a key regulator in cellular processes. The orchestrated interplay of these regulatory elements amplifies Foxl3's involvement in the intricate dance of genetic expression, steering cellular pathways toward anatomical structure morphogenesis and fostering cell differentiation. Unraveling the specific details of Foxl3 activation provides a deeper understanding of its functional significance in cellular physiology, shedding light on the intricate web of interactions that govern its transcriptional activity and cellular functions.
SEE ALSO...
Items 1 to 10 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor known to disrupt the degradation of ubiquitinated proteins. Inhibiting the proteasome can lead to the accumulation of regulatory proteins that may normally be degraded, thereby indirectly inhibiting CCDC35 by potentially promoting the degradation of proteins that stabilize CCDC35. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid up-regulates Foxl3 by binding to retinoic acid receptors, leading to enhanced transcriptional activity. It promotes Foxl3 involvement in anatomical structure morphogenesis and cell differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can lead to the downregulation of the PI3K/AKT pathway, potentially affecting CCDC35 which may require PI3K/AKT signaling for its stabilization or function within the cell. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A stimulates Foxl3 by inhibiting histone deacetylases, resulting in increased acetylation of histones. This epigenetic modification promotes Foxl3's role in transcriptional regulation and cell differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor which suppresses the PI3K/AKT pathway, potentially resulting in the reduced activity of downstream effectors that could stabilize CCDC35, thereby indirectly inhibiting its function. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate enhances Foxl3 activation by inhibiting histone deacetylases. This leads to increased histone acetylation, facilitating Foxl3-mediated transcription and contributing to cell differentiation processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 indirectly activates Foxl3 by inhibiting TGF-β signaling. Suppression of TGF-β prevents its inhibitory influence on Foxl3, promoting its transcriptional activity in the regulation of cell differentiation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A kinase inhibitor that broadly targets protein kinases, possibly leading to the inhibition of kinases that phosphorylate CCDC35 or its associated proteins, thus indirectly reducing CCDC35 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2 that disrupts the MAPK/ERK pathway, which may regulate CCDC35 indirectly by affecting the phosphorylation status of proteins interacting with CCDC35, thus inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that might lead to decreased activation of downstream targets that could be involved in CCDC35 stabilization or activity, resulting in the indirect inhibition of CCDC35. | ||||||